Hakami Abrar, Rizzo Sebastiano Antonio, Bartley Oliver J M, Hills Rachel, Precious Sophie V, Ostler Timothy, Fjodorova Marija, Alghamdi Majed, Rosser Anne E, Lane Emma L, Woolley Thomas E, Lelos Mariah J, Newland Ben
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3NB, UK; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3NB, UK.
Neurotherapeutics. 2025 Mar;22(2):e00518. doi: 10.1016/j.neurot.2024.e00518. Epub 2025 Jan 9.
Replacing cells lost during the progression of neurodegenerative disorders holds potential as a therapeutic strategy. Unfortunately, the majority of cells die post-transplantation, which creates logistical and biological challenges for cell therapy approaches. The cause of cell death is likely to be multifactorial in nature but has previously been correlated with hypoxia in the graft core. Here we use mathematical modelling to highlight that grafted cells experiencing hypoxia will also face a rapid decline in glucose availability. Interestingly, three neuron progenitor types derived from stem cell sources, and primary human fetal ventral mesencephalic (VM) cells all remained highly viable in severe hypoxia (0.1 % oxygen), countering the idea of rapid hypoxia-induced death in grafts. However, we demonstrate that glucose deprivation, not a paucity of oxygen, was a driver of rapid cell death, which was compounded in ischemic conditions of both oxygen and glucose deprivation. Supplementation of glucose to rat embryonic VM cells transplanted to the adult rat brain failed to improve survival at the dose administered and highlighted the problems of using osmotic minipumps in assisting neural grafting. The data shows that maintaining sufficient glucose in grafts is likely to be of critical importance for cell survival, but better means of achieving sustained glucose delivery is required.
替换神经退行性疾病进展过程中损失的细胞作为一种治疗策略具有潜力。不幸的是,大多数细胞在移植后死亡,这给细胞治疗方法带来了后勤和生物学方面的挑战。细胞死亡的原因可能是多因素的,但此前已与移植核心部位的缺氧相关。在这里,我们使用数学模型来强调经历缺氧的移植细胞也将面临葡萄糖可用性的快速下降。有趣的是,源自干细胞来源的三种神经元祖细胞类型以及原代人胎儿腹侧中脑(VM)细胞在严重缺氧(0.1%氧气)条件下都保持了高度的活力,这与移植中缺氧快速导致死亡的观点相悖。然而,我们证明葡萄糖剥夺而非氧气缺乏是细胞快速死亡的驱动因素,在氧气和葡萄糖都缺乏的缺血条件下这种情况会加剧。向移植到成年大鼠大脑的大鼠胚胎VM细胞补充葡萄糖,在所施用的剂量下未能提高存活率,并突出了使用渗透微型泵辅助神经移植的问题。数据表明,在移植中维持足够的葡萄糖对细胞存活可能至关重要,但需要更好的方法来实现持续的葡萄糖递送。